Business Description
![Pacira BioSciences Inc Pacira BioSciences Inc logo](https://static.gurufocus.com/logos/0C00008EGN.png?14)
Pacira BioSciences Inc
NAICS : 325412
SIC : 2834
ISIN : US6951271005
Description
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.56 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.65 | |||||
Debt-to-EBITDA | 3.1 | |||||
Interest Coverage | 8.27 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.05 | |||||
Beneish M-Score | -2.81 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.7 | |||||
3-Year EBITDA Growth Rate | 26.9 | |||||
3-Year EPS without NRI Growth Rate | -32.2 | |||||
3-Year FCF Growth Rate | 44 | |||||
3-Year Book Growth Rate | 9.6 | |||||
Future 3-5Y EPS without NRI Growth Rate | 9.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 7.26 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.33 | |||||
9-Day RSI | 41.98 | |||||
14-Day RSI | 43.68 | |||||
6-1 Month Momentum % | -13.47 | |||||
12-1 Month Momentum % | -25.31 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.81 | |||||
Quick Ratio | 4.78 | |||||
Cash Ratio | 3.49 | |||||
Days Inventory | 192.51 | |||||
Days Sales Outstanding | 53.16 | |||||
Days Payable | 32.96 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.1 | |||||
Shareholder Yield % | 12.75 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 73.15 | |||||
Operating Margin % | 13.7 | |||||
Net Margin % | 10.34 | |||||
FCF Margin % | 25.4 | |||||
ROE % | 8.45 | |||||
ROA % | 4.54 | |||||
ROIC % | 5.25 | |||||
ROC (Joel Greenblatt) % | 30.08 | |||||
ROCE % | 7.78 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 19.73 | |||||
Forward PE Ratio | 10.6 | |||||
PE Ratio without NRI | 12.76 | |||||
Shiller PE Ratio | 86.7 | |||||
Price-to-Owner-Earnings | 11.7 | |||||
PEG Ratio | 0.34 | |||||
PS Ratio | 2.29 | |||||
PB Ratio | 1.49 | |||||
Price-to-Tangible-Book | 5.12 | |||||
Price-to-Free-Cash-Flow | 9.1 | |||||
Price-to-Operating-Cash-Flow | 8.52 | |||||
EV-to-EBIT | 13.75 | |||||
EV-to-EBITDA | 8.29 | |||||
EV-to-Revenue | 2.28 | |||||
EV-to-Forward-Revenue | 2.26 | |||||
EV-to-FCF | 8.98 | |||||
Price-to-Projected-FCF | 0.92 | |||||
Price-to-Median-PS-Value | 0.44 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.51 | |||||
Price-to-Graham-Number | 1.7 | |||||
Earnings Yield (Greenblatt) % | 7.27 | |||||
FCF Yield % | 13.01 | |||||
Forward Rate of Return (Yacktman) % | 26.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PCRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pacira BioSciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 681.754 | ||
EPS (TTM) ($) | 1.45 | ||
Beta | 0.46 | ||
Volatility % | 38.3 | ||
14-Day RSI | 43.68 | ||
14-Day ATR ($) | 0.994087 | ||
20-Day SMA ($) | 28.7945 | ||
12-1 Month Momentum % | -25.31 | ||
52-Week Range ($) | 25.33 - 40.45 | ||
Shares Outstanding (Mil) | 46.55 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Pacira BioSciences Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Pacira BioSciences Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Pacira BioSciences Inc Frequently Asked Questions
What is Pacira BioSciences Inc(PCRX)'s stock price today?
The current price of PCRX is $28.61. The 52 week high of PCRX is $40.45 and 52 week low is $25.33.
When is next earnings date of Pacira BioSciences Inc(PCRX)?
The next earnings date of Pacira BioSciences Inc(PCRX) is 2024-08-02 Est..
Does Pacira BioSciences Inc(PCRX) pay dividends? If so, how much?
Pacira BioSciences Inc(PCRX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |